CDKN2A and glioma: Introduction of IDH1-mut into transgenic mouse gliomas with different genetic background, expressing platelet-derived growth factor alpha (PDGFα), shp53, or Ink4a/Arf+/+ and Ink4a/Arf+/−, demonstrated significantly shorter survival compared to mice with IDH1-wt tumors.